ASCO GI Conference Coverage
Filter News By:
Featured News
(2020 GI Cancers Symposium) Jan 24, 2020 - Positive findings from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study cohorts on the potential benefit of various molecularly targeted drugs in patients with advanced colorectal cancer will be presented at the 2020 Gastrointestinal Cancers Symposium, taking place January...
(2020 GI Cancers Symposium) Jan 21, 2020 - Patient-reported outcomes from two large studies show that quality of life is maintained longer with newer drug combinations compared with standard of care for the treatment of patients with a specific type of colorectal cancer and unresectable hepatocellular carcinoma. The combination of...
(2020 GI Cancers Symposium) Jan 21, 2020 - A blood-based screening test using cell-free DNA to identify methylation signals of hard-to-detect gastrointestinal (GI) cancers that could potentially help detect cancer at earlier stages will be presented 2020 Gastrointestinal Cancers Symposium, taking place January 23-25 in San Francisco,...
(2020 GI Cancers Symposium) Jan 21, 2020 - A retrospective analysis of 26,768 young adults age 40 and under found that those who live in areas with lower income (less than $38,000) and lower education (under 79% high school graduation rate), as well as those who live in urban areas, had worse outcomes and a higher risk of death. The...
View all
More News
(Medscape Medical News) Feb 18, 2020 - Should the age be lowered in view of the mounting reports of an increase in CRC in younger adults? Experts argued both for and against the move here at the 2020 Gastrointestinal Cancers Symposium.
(Medscape Medical News) Jan 27, 2020 - For patients with unresectable hepatocellular carcinoma (HCC), the combination of atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) has already shown better efficacy than standard treatment with sorafenib (Nexavar, Bayer) in the IMbrave150 trial.
(MedPage Today) Jan 25, 2020 - Only the two-drug combination of encorafenib (Braftovi) plus cetuximab (Erbitux) will undergo regulatory review by the FDA for metastatic BRAF-mutant colorectal cancer at this time, a researcher reported here.
(MedPage Today) Jan 24, 2020 - So-called switch maintenance with an immune checkpoint inhibitor failed to improve overall survival (OS) in treatment-naive HER2-negative advanced gastric or gastroesophageal junction cancer, results of a phase III trial found.
(MedPage Today) Jan 26, 2020 - Resection of the primary tumor ahead of chemotherapy yielded no survival benefit for newly diagnosed metastatic colorectal cancer (CRC) patients with asymptomatic primaries, a randomized trial from Japan found.
(Medscape Medical News) Jan 24, 2020 - Escalating the dose of radiation therapy does not appear to improve outcomes for patients with esophageal cancer who are receiving definitive chemoradiation, according to new findings.
(Taiho Oncology) Jan 25, 2020 - Taiho Oncology, Inc. announced today the presentation of a pooled analysis for hematologic adverse events of the global Phase III TAGS and RECOURSE trials evaluating LONSURF® (trifluridine and tipiracil) in patients with metastatic colorectal cancer (mCRC) and metastatic gastric or gastroesophageal...
(Yahoo! News) Jan 27, 2020 - All patients showed tumor regression by radiographic scan at 8 weeks and confirmation by further tumor shrinkage at 16 weeks; clinical benefit achieved in 100% (n=5) of patients.
(Yahoo! Finance) Jan 25, 2020 - NantHealth, Inc. today announced results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients during a poster session at the 2020 GI.
(Yahoo! Finance) Jan 27, 2020 - AVEO Oncology and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with nab-paclitaxel and gemcitabine in patients with previously...
(Bellicum) Jan 24, 2020 - Bellicum Pharmaceuticals, Inc. today presented new Phase 1 translational results for BPX-601 at the 2020 GI Cancers Symposium in San Francisco.
(Oncolytics Biotech) Jan 27, 2020 - Over 80% improvement in progression free survival in patients with low levels of CEACAM6.
(Sun BioPharma) Jan 24, 2020 - SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel. Objective Response Rate (ORR) was 62% by RECIST criteria.
(Yahoo! Finance) Jan 27, 2020 - Global NuTide:121 study is enrolling up to 828 patients and comparing acelarin plus cisplatin to gemcitabine plus cisplatin.
Featured Videos
There are no featured ASCO GI Conference Coverage videos.
More Videos
There are no ASCO GI Conference Coverage videos.

OBR Tweets

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye